LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 757 | 3694 | 0.2051 | -0.3243 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 843 | 3694 | 0.2283 | -0.2857 |
| SK-BR-3 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 1476 | 3712 | 3694 | 1.0049 | 1.0081 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 765 | 3694 | 0.2073 | -0.3207 |
| SK-BR-3 | GSK 690693 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 3105 | 3694 | 0.8406 | 0.7345 |
| SK-BR-3 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2206 | 3694 | 0.5974 | 0.3292 |
| SK-BR-3 | HG-5-113-01 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1296 | 3694 | 0.3509 | -0.0814 |
| SK-BR-3 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1696 | 3694 | 0.4591 | 0.0989 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 3656 | 3694 | 0.9898 | 0.9830 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1203 | 3694 | 0.3258 | -0.1233 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1074 | 3694 | 0.2907 | -0.1816 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1740 | 3694 | 0.4712 | 0.1190 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 662 | 3694 | 0.1794 | -0.3671 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1846 | 3694 | 0.4999 | 0.1668 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2480 | 3694 | 0.6715 | 0.4528 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 1476 | 630 | 3694 | 0.1707 | -0.3816 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1476 | 544 | 3694 | 0.1474 | -0.4204 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1342 | 3694 | 0.3634 | -0.0606 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1080 | 3694 | 0.2924 | -0.1789 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2005 | 3694 | 0.5428 | 0.2383 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 977 | 3694 | 0.2646 | -0.2252 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1761 | 3694 | 0.4768 | 0.1284 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1602 | 3694 | 0.4339 | 0.0568 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 965 | 3694 | 0.2613 | -0.2306 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2583 | 3694 | 0.6993 | 0.4991 |